Susan Levinson

Susan Levinson has a long and varied career in the pharmaceutical and biotechnology industries. Susan began their career in 1974 as a Postdoctoral Fellow-Roche Institute at Hoffmann-La Roche. Susan then moved to Revlon Health Care in 1975 as a Scientist, and to Johnson & Johnson; Ortho Pharmaceutical in 1978 as a Principal Scientist. In 1989, they joined Ciba-Geigy Pharmaceuticals as Director, Licensing, where they negotiated and closed six contracts. In 1993, they became Director, New Product Commercialization at Ciba-Geigy Pharmaceuticals, responsible for maximizing commercial potential of R & D portfolio and assessment of external opportunities. In 1996, they joined Novartis Pharmaceuticals as Director, Marketing Operations, Planning; Director, Business Strategy; Brand Management, creating, building and improving operational capabilities to support execution of marketing activity for all promoted products. In 2006, they founded The Strategic Choice LLC and served as President. In 2011, they became Chief Executive Officer at BioAegis Therapeutics, Inc., developing a human protein therapeutic which modulates inflammation and boosts immune function. In 2013, they founded Azure Biotech Inc., a private biotechnology company which has acquired rights for development of a novel formulation of lasofoxifene. Finally, in 2021, they joined BioNJ as a Board of Trustees.

Susan Levinson obtained their Bachelor of Science degree in Biochemistry from the University of Wisconsin-Madison in 1971. Susan then went on to pursue a PhD in Biomedical Sciences from the Icahn School of Medicine at Mount Sinai, which they completed in 1975. Prior to that, they attended Jonathan Dayton Regional High School.